• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.

作者信息

Kockerols Camille C B, Janssen Jeroen J W M, Blijlevens Nicole M A, Klein Saskia K, Van Hussen-Daenen Laura G M, Van Gorkom Gwendolyn G Y, Smit Willem M, Van Balen Peter, Biemond Bart J, Cruijsen Marjan J, Corsten Maarten F, Te Boekhorst Peter A W, Koene Harry R, Van Sluis Geerte L, Cornelissen Jan J, Westerweel Peter E

机构信息

Department of Internal Medicine, Albert Schweitzer Hospital.

Department of Hematology, Amsterdam University Medical Centers, location VUMC.

出版信息

Haematologica. 2023 Jan 1;108(1):240-244. doi: 10.3324/haematol.2022.281386.

DOI:10.3324/haematol.2022.281386
PMID:36073515
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9827157/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6463/9827157/7db99802582e/108240.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6463/9827157/24093de4fc14/108240.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6463/9827157/7db99802582e/108240.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6463/9827157/24093de4fc14/108240.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6463/9827157/7db99802582e/108240.fig2.jpg

相似文献

1
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.阿伐替尼在真实世界多耐药慢性髓性白血病患者群体中的治疗模式及临床结局
Haematologica. 2023 Jan 1;108(1):240-244. doi: 10.3324/haematol.2022.281386.
2
Asciminib as a new option in the treatment of chronic myeloid leukemia.阿塞西尼布作为慢性粒细胞白血病治疗的新选择。
Future Oncol. 2021 Dec;17(36):5003-5005. doi: 10.2217/fon-2021-1174. Epub 2021 Nov 18.
3
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.阿斯科利尼布治疗慢性髓性白血病患者在现实临床实践中的安全性和有效性。
Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8.
4
Asciminib in chronic myeloid leukemia: many questions still remain to be answered.阿伐替尼治疗慢性髓性白血病：仍有许多问题有待解答。
Blood Cancer J. 2021 Apr 29;11(4):81. doi: 10.1038/s41408-021-00475-7.
5
Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting.打破常规：阿伐替尼作为一线慢性髓性白血病治疗武器库中的标准治疗药物。
Future Oncol. 2023 Mar;19(8):545-547. doi: 10.2217/fon-2023-0095. Epub 2023 Apr 11.
6
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.使用阿斯科利尼布和博舒替尼联合抑制BCR-ABL克服慢性髓性白血病患者的TKI耐药性。
Am J Hematol. 2021 Aug 1;96(8):E293-E295. doi: 10.1002/ajh.26231. Epub 2021 May 25.
7
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.移植后阿塞西尼布治疗慢性髓性白血病患者的疗效
Bone Marrow Transplant. 2023 Jul;58(7):826-828. doi: 10.1038/s41409-023-01975-9. Epub 2023 Apr 4.
8
Asciminib (Scemblix) for chronic myeloid leukemia.阿伐替尼（Scemblix）用于治疗慢性粒细胞白血病。
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e107-e108. doi: 10.58347/tml.2023.1678g.
9
Asciminib for the treatment of patients with chronic myeloid leukemia.阿伐替尼用于治疗慢性髓性白血病患者。
Clin Adv Hematol Oncol. 2021 Apr;19(4):207-208.
10
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.ASCIMINIB 的特异性，一种治疗慢性髓性白血病的潜在药物，作为一种豆蔻酰口袋结合的 ABL 抑制剂，并分析其与 BCR-ABL1 激酶突变形式的相互作用。
Leuk Res. 2020 Nov;98:106458. doi: 10.1016/j.leukres.2020.106458. Epub 2020 Sep 29.

引用本文的文献

1
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.2025年欧洲白血病网慢性髓性白血病管理建议
Leukemia. 2025 Jul 11. doi: 10.1038/s41375-025-02664-w.
2
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysis.阿伐替尼作为慢性髓性白血病二线或二线以上治疗方案治疗患者的疗效和安全性：一项系统评价与荟萃分析
Ther Adv Hematol. 2025 Jun 10;16:20406207251342203. doi: 10.1177/20406207251342203. eCollection 2025.
3
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.

本文引用的文献

1
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.一项 3 期、开放标签、随机研究，评估了 STAMP 抑制剂 ASCiminib 与博舒替尼（一种二代 TKI）在 2 种或更多种 TKI 治疗后 CML 患者中的疗效。
Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984.
2
Third-line therapy for chronic myeloid leukemia: current status and future directions.慢性髓性白血病的三线治疗：现状与未来方向。
J Hematol Oncol. 2021 Mar 18;14(1):44. doi: 10.1186/s13045-021-01055-9.
3
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
阿西替尼在意大利多耐药慢性期慢性髓性白血病（CML-CP）患者群体中同情用药的真实世界疗效概况。
Hematol Oncol. 2025 May;43(3):e70101. doi: 10.1002/hon.70101.
4
Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia.阿伐替尼在经大量预处理的慢性髓性白血病患者中的真实世界毒性和疗效
Int J Hematol. 2025 Feb;121(2):187-193. doi: 10.1007/s12185-024-03873-2. Epub 2024 Nov 19.
5
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.BCR::ABL1 单核苷酸变异对 asciminib 疗效的影响。
Leukemia. 2024 Nov;38(11):2443-2455. doi: 10.1038/s41375-024-02411-7. Epub 2024 Sep 17.
6
Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy.第二代酪氨酸激酶抑制剂治疗失败后慢性髓性白血病的治疗选择
Front Oncol. 2024 Jul 29;14:1446517. doi: 10.3389/fonc.2024.1446517. eCollection 2024.
7
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.阿西替尼在真实临床实践中的毒性：副作用分析及与酪氨酸激酶抑制剂的交叉毒性
Cancers (Basel). 2023 Feb 7;15(4):1045. doi: 10.3390/cancers15041045.
阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.